Fig. 2From: SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetesA 1-year HbA1c mean levels in never SGLT2i users (n = 200) and current SGLT2i users (N = 177), boxplots display the median, 25th, and 75th percentiles, range, and extreme values. B Intra-stent restenosis rate during 1-year follow-up in never SGLT2i users (n = 200) and current SGLT2i users (N = 177), *P < 0.05 vs never SGLT2i users. C, D Minimum lumen diameter (MLD) and minimal luminal area (MLA) of treated coronary by coronary CT angiography at 1-year follow-up in never SGLT2i users (n = 156) and current SGLT2i users (N = 159) without intra-stent restenosis-related events, *P < 0.05 vs never SGLT2i users. Boxplots display the median, 25th, and 75th percentiles, range, and extreme valuesBack to article page